Nebulized recombinant tissue plasminogen activator (rt-PA) for acute COVID-19-induced severe respiratory failure: an exploratory proof of concept trial
Nebulized thrombolysis offers locally targeted therapy with potentially lower bleeding risk than systemic administration for coronavirus disease 2019 (COVID-19) respiratory failure. In a proof-of-concept safety study, adult patients with COVID-19-induced respiratory failure and a <300mmHg PaO2/FiO2 (P/F) ratio, requiring invasive mechanical ventilation (IMV) or non-invasive respiratory support (NIRS) received nebulized rt-PA in two cohorts (C1 and C2), alongside standard of care during the first two UK COVID-19 waves. Matched historical controls (MHC; n=18) were used in C1. Safety co-primary endpoints were treatment-related bleeds and fibrinogen reduction to <1.0–1.5 g/L. A dose escalation strategy for improved efficacy with the least safety concerns was determined in C1 for use in C2; patients were stratified by ventilation type to receive 40–60 mg rt-PA per day for ≤14 days. Nine patients in C1 (IMV, 6/9; NIRS, 3/9) and 26 in C2 (IMV, 12/26; NIRS, 14/26) received nebulized rt-PA for a mean (SD) of 6.7 (4.6) and 9.1(4.6) days, respectively. Four bleeding events (one severe and three mild) in three patients were considered treatment-related. No significant fibrinogen reductions were reported. Greater improvement in mean P/F ratio from baseline to end of study was observed in C1 compared with MHC [C1; 154 to 299 vs MHC; 154 to 212). In C2, there was no difference in the baseline P/F ratio of NIRS and IMV patients. However, a larger improvement in P/F ratio was observed in NIRS patients [NIRS; 126 to 240 vs IMV; 120 to 188) and they required fewer treatment days (NIRS; 7.86 vs IMV; 10.5). Nebulized rt-PA appears to be well-tolerated, showing a trend of improved oxygenation and faster recovery in patients with acute COVID-19-induced respiratory failure requiring respiratory support; this effect was more pronounced in the NIRS group. Further investigation is required to study the potential of this novel treatment approach..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Preprints.org - (2023) vom: 14. Sept. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chowdary, Pratima [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.20944/preprints202306.1455.v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
preprintsorg039959201 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | preprintsorg039959201 | ||
| 003 | DE-627 | ||
| 005 | 20231205144830.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230621s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.20944/preprints202306.1455.v1 |2 doi | |
| 024 | 7 | |a 10.20944/preprints202306.1455.v1 |2 doi | |
| 035 | |a (DE-627)preprintsorg039959201 | ||
| 035 | |a (preprintsorg)10.20944/preprints202306.1455 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chowdary, Pratima |e verfasserin |0 (orcid)0000-0002-6690-8586 |4 aut | |
| 245 | 1 | 0 | |a Nebulized recombinant tissue plasminogen activator (rt-PA) for acute COVID-19-induced severe respiratory failure: an exploratory proof of concept trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Nebulized thrombolysis offers locally targeted therapy with potentially lower bleeding risk than systemic administration for coronavirus disease 2019 (COVID-19) respiratory failure. In a proof-of-concept safety study, adult patients with COVID-19-induced respiratory failure and a <300mmHg PaO2/FiO2 (P/F) ratio, requiring invasive mechanical ventilation (IMV) or non-invasive respiratory support (NIRS) received nebulized rt-PA in two cohorts (C1 and C2), alongside standard of care during the first two UK COVID-19 waves. Matched historical controls (MHC; n=18) were used in C1. Safety co-primary endpoints were treatment-related bleeds and fibrinogen reduction to <1.0–1.5 g/L. A dose escalation strategy for improved efficacy with the least safety concerns was determined in C1 for use in C2; patients were stratified by ventilation type to receive 40–60 mg rt-PA per day for ≤14 days. Nine patients in C1 (IMV, 6/9; NIRS, 3/9) and 26 in C2 (IMV, 12/26; NIRS, 14/26) received nebulized rt-PA for a mean (SD) of 6.7 (4.6) and 9.1(4.6) days, respectively. Four bleeding events (one severe and three mild) in three patients were considered treatment-related. No significant fibrinogen reductions were reported. Greater improvement in mean P/F ratio from baseline to end of study was observed in C1 compared with MHC [C1; 154 to 299 vs MHC; 154 to 212). In C2, there was no difference in the baseline P/F ratio of NIRS and IMV patients. However, a larger improvement in P/F ratio was observed in NIRS patients [NIRS; 126 to 240 vs IMV; 120 to 188) and they required fewer treatment days (NIRS; 7.86 vs IMV; 10.5). Nebulized rt-PA appears to be well-tolerated, showing a trend of improved oxygenation and faster recovery in patients with acute COVID-19-induced respiratory failure requiring respiratory support; this effect was more pronounced in the NIRS group. Further investigation is required to study the potential of this novel treatment approach. | ||
| 700 | 1 | |a Agarwal, Banwari |0 (orcid)0000-0001-5508-2590 |4 aut | |
| 700 | 1 | |a Peralta, Maria Rita |4 aut | |
| 700 | 1 | |a Bhagani, Sanjay |4 aut | |
| 700 | 1 | |a Lee, Simon |4 aut | |
| 700 | 1 | |a Goldring, James |4 aut | |
| 700 | 1 | |a Lipman, Marc |4 aut | |
| 700 | 1 | |a Waqif, Emal |4 aut | |
| 700 | 1 | |a Phillips, Mark |4 aut | |
| 700 | 1 | |a Philippou, Helen |4 aut | |
| 700 | 1 | |a Foley, Jonathan H |4 aut | |
| 700 | 1 | |a Mutch, Nicola J |0 (orcid)0000-0002-7452-0813 |4 aut | |
| 700 | 1 | |a Ariens, Robert |4 aut | |
| 700 | 1 | |a Stringer, Kathleen A |0 (orcid)0000-0003-0238-7774 |4 aut | |
| 700 | 1 | |a Ricciardi, Federico |4 aut | |
| 700 | 1 | |a Watissée, Marie |4 aut | |
| 700 | 1 | |a Hughes, Derralynn |4 aut | |
| 700 | 1 | |a Nathwani, Amit |4 aut | |
| 700 | 1 | |a Riddell, Anne |4 aut | |
| 700 | 1 | |a Patch, David |4 aut | |
| 700 | 1 | |a Buckley, Jim |4 aut | |
| 700 | 1 | |a De Neef, Mark |4 aut | |
| 700 | 1 | |a Dimber, Rahul |0 (orcid)0000-0003-4207-3411 |4 aut | |
| 700 | 1 | |a Diaz-Garcia, Cecilia |4 aut | |
| 700 | 1 | |a Patel, Honey |4 aut | |
| 700 | 1 | |a Nandani, Aarti |4 aut | |
| 700 | 1 | |a Dissanayake, Upuli |4 aut | |
| 700 | 1 | |a Chadwick, Nick |4 aut | |
| 700 | 1 | |a Alkhatip, Ahmed |4 aut | |
| 700 | 1 | |a Watkinson, Peter |4 aut | |
| 700 | 1 | |a Raith, Eamon |4 aut | |
| 700 | 1 | |a Singh, Suveer |0 (orcid)0000-0003-3219-8966 |4 aut | |
| 700 | 1 | |a Wolff, Tony |4 aut | |
| 700 | 1 | |a Jha, Rajeev |4 aut | |
| 700 | 1 | |a Brill, Simon E |4 aut | |
| 700 | 1 | |a Bakhai, Ameet |4 aut | |
| 700 | 1 | |a Evans, Alison |4 aut | |
| 700 | 1 | |a Gilani, Farhat |4 aut | |
| 700 | 1 | |a Gomez, Keith |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Preprints.org |g (2023) vom: 14. Sept. |
| 773 | 1 | 8 | |g year:2023 |g day:14 |g month:09 |
| 856 | 4 | 0 | |u https://doi.org/10.3390/jcm12185848 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.20944/preprints202306.1455.v1 |z kostenfrei |3 Volltext |
| 912 | |a preprintsorg | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 14 |c 09 | ||